Early neurological deterioration after intravenous thrombolysis of anterior vs posterior circulation stroke: a secondary analysis of INTRECIS

• Published in: Scientific reports Vol. 12; no. 1; p. 3163
• Main Authors: Cui, Yu, Meng, Wei-Hong, Chen, Hui-Sheng
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 24.02.2022; Nature Publishing Group; Nature Portfolio
• Subjects: 631/378; 692/617; Aged; Brain Ischemia - drug therapy; Brain Ischemia - physiopathology; Cerebrovascular Circulation; Female; Fibrillation; Fibrinolysis; Fibrinolytic Agents - therapeutic use; Humanities and Social Sciences; Humans; Hypertension; Intravenous administration; Male; Middle Aged; multidisciplinary; Prospective Studies; Risk Factors; Science; Science (multidisciplinary); Secondary analysis; Stroke; Stroke - drug therapy; Stroke - physiopathology; Territory; Thrombolysis; Thrombolytic Therapy - methods; Tissue Plasminogen Activator - therapeutic use; Treatment Outcome
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-022-07095-6

Anterior circulation stroke (ACS) differs from posterior circulation stroke (PCS) in many ways, but it remains unclear whether there is any difference in early neurological deterioration (END) in two stroke territories. We compared post-thrombolytic END between ACS and PCS based on the data from INTRECIS. We screened patients receiving intravenous 0.9 mg/kg alteplase within 4.5 h in the INTRECIS cohort. According to stroke territory, patients were divided into ACS and PCS groups. The primary outcome was incidence of END, which was defined as an increase in NIHSS score ≥ 4 or death within 24 h from baseline. The secondary outcomes were associated factors of END and 90-day modified Rankin Scale (mRS) distribution. Overall, 1194 patients were enrolled in this study: 942 in ACS group and 252 in PCS group. There was no significant difference in the incidence of END between two groups (3.8% vs 5.2%, adjusted p  = 0.406). Atrial fibrillation (adjusted p  = 0.012) and TOAST classification (adjusted p  = 0.009) were associated with END in ACS, while hypertension history (adjusted p  = 0.046) and baseline NIHSS score (adjusted p  = 0.011) with END in PCS. END was associated with worse outcome on 90-day mRS in ACS and PCS (adjusted p  < 0.001). Based on a prospective nationwide cohort, we provided first report for similar incidence, but different risk factors of post-thrombolytic END in ACS vs PCS patients. Trial Registration-URL : https://www.clinicaltrials.gov ; Unique identifier: NCT02854592.